This company listing is no longer active
Acorda Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Acorda Therapeutics has a total shareholder equity of $67.9M and total debt of $176.2M, which brings its debt-to-equity ratio to 259.6%. Its total assets and total liabilities are $364.7M and $296.8M respectively.
Key information
259.6%
Debt to equity ratio
US$176.16m
Debt
| Interest coverage ratio | n/a |
| Cash | US$25.27m |
| Equity | US$67.87m |
| Total liabilities | US$296.83m |
| Total assets | US$364.70m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CDG's short term assets ($64.9M) exceed its short term liabilities ($30.4M).
Long Term Liabilities: CDG's short term assets ($64.9M) do not cover its long term liabilities ($266.4M).
Debt to Equity History and Analysis
Debt Level: CDG's net debt to equity ratio (222.3%) is considered high.
Reducing Debt: CDG's debt to equity ratio has increased from 55.9% to 259.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CDG has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 25.1% each year.